Abstract:

Antiretroviral pre-exposure prevention (PrEP) to stop HIV transmission was 1st approved by the USA Food and Drug Administration in 2012. Despite correlations of decreases in new HIV infections being greatest wherever PrE-exposure prophylaxis has been deployed, the uptake of PrE-exposure prophylaxis is insulant, significantly among populations with disproportionate HIV burden. This narrative review seeks to spot individual and general barriers to PrE-exposure prophylaxis usage in African country. A comprehensive search of recent literature uncovered a fancy array of structural, social, clinical, and behavioral barriers, as well as knowledge/awareness of PrE exposure prophylaxis, perception of HIV risk, stigma from care suppliers or family/partners/friends, distrust of care providers/systems, access to school assignment, prices of PrE exposure prophylaxis, and issues around school assignment facet effects/medication interactions. significantly, these barriers might have totally different effects on specific populations in danger. The complete potential of PrE-exposure prophylaxis for HIV interference won't be realized till these problems area unit self-addressed. Ways to realize this goal ought to embody academic interventions, innovative approaches to delivery of HIV care, resource, and DE stigmatization of PrE-exposure prophylaxis and PrE-exposure prophylaxis users. Until then, PrE-exposure prophylaxis `uptake can still be suboptimal, significantly among people who would like it most. Results: Stigma influences uptake of pre-exposure prophylaxis; HIV risk perception does not affect uptake of pre-exposure prophylaxis; and a significant negative relationship between stigma and pre-exposure prophylaxis uptake. Conclusion: This study was conducted to investigate barriers to oral pre-exposure prophylaxis. Significant findings of the study conclude: stigma influences uptake of oral pre-exposure prophylaxis for HIV.

References:

[1] Strug, DL et al, 2002, Challenges and Changing Roles in HIV/AIDS Social Work, Social Work in Health Care, Volume 35, 2002 - Issue 4, p. 1 -19. https://doi.org/10.1300/J010v35n04_01.

[2] U Koppe · 2021 Barriers to using Pre-Exposure prophylaxis (PrEP).

[3] Fonner VA et al. (2016) ‘Effectiveness and safety of oral HIV pre-exposure prophylaxis for all populations’, AIDS, Volume 30, Issue 12, p.1973–83.

[4] McCormack, S et al. (2014) ‘Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial’, The Lancet, Volume 387, Issue 10013, p.53-60.

[5] Baeten, JM et al. (2012) 'Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women', New England Journal of Medicine, Volume 367, Issue 5, p.399-410.

[6] Grant, RM et al. (2010) 'Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men', New England Journal of Medicine, Volume 363, p.2587-2599.

[7] BBC (10 April 2017) ‘NHS Scotland to fund 'game-changer' Prep HIV drug’.

[8] Public Health Society of Kenya (2017) ‘Why PrEP tool is a game-changer in fight against spread of HIV.

[9] San Francisco Bay Times ‘PrEP Could Be a Game Changer in the Fight Against HIV/AIDS’ (all accessed April 2019).

[10] Goffman, E. (1963). Stigma. Notes on the Management of Spoiled Identity. London: Penguin Books.

[11] World Health Organization (WHO) (2015) 'Policy brief: WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)' [pdf].

[12] San Francisco Department of Public Health, Population Health Division (2015) 'HIV Epidemiology Annual Report 2014' [pdf].

[13] World Health Organization (WHO) (2015) 'Policy brief: WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)' [pdf].

[14] UNAIDS (2018) ‘Miles to go: global AIDS update 2018’, p.59. [pdf].

[15] Prince O. Ezekiel (2022), Investigating the Effectiveness of Case Management among Orphans and Vulnerable Children at Household Level in Enugu State, Nigeria. Texila International Journal of Academic Research Special Edition Apr 2022, https://www.texilajournal.com/academic-research/article/2035-investigating-the-effectiveness.

[16] Aidsmap (2016) ‘Two cases of PrEP failure on solo tenofovir pose significant research questions’ (accessed April 2019).

[17] US Department of Health and Human Sciences: AIDSinfo ‘Maraviroc (HIV prevention)’ (accessed April 2019).

[18] Aidsmap (2015) 'Evidence for PrEP efficacy grows, but implementation presents challenges' (accessed April 2019).

[19] Centers for Disease Control and Prevention (CDC) ‘PrEP’ (accessed April 2019).

[20] Simon J, Agada1 and Prince Ezekiel (2023), Barriers to HIV Testing among Clients of Female Sex Workers an Assessment of Ogoja Local Government Area, Texila International Journal of Public Health: 2520-3134, https://doi.org/10.21522/TIJPH.2013.11.01.Art016.

[21] Hiv.gov/basics of hiv, retrieved on 18th November 2021.

[22] Centers for Disease Control and Prevention. Application number: 021752Orig1s030 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021752Orig1s030SumR.pdf.

[23] HIV and AIDS in Kenya. https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/kenya Accessed 15 Apr 2020.

[24] Ramjee G, Daniels B. Women and HIV in sub-Saharan Africa. AIDS Res Ther. 2013;10(1):30. https://doi.org/10.1186/1742-6405-10-30.

[25] UNAIDS. Advocating for zero discrimination in health-care settings in Kenya 2018. https://www.unaids.org/en/resources/presscentre/featurestories/2018/may/zero-discrimination-health-care-settings-kenya.

[26] Thomson K, Baeten J, Mugo N, Bekker L, Celum C, Heffron R. (2016), Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS.;11(1):18–26.

[27] Jackson-Gibson, M., Ezema, A.U., Orero, W. et al. (2021), Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya. BMC Public Health 21, 1284 https://doi.org/10.1186/s12889-021-11335-1.